2,795 Shares in Danaher Corporation $DHR Acquired by Cultivar Capital Inc.

Cultivar Capital Inc. bought a new position in shares of Danaher Corporation (NYSE:DHR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,795 shares of the conglomerate’s stock, valued at approximately $619,000. Danaher comprises 0.4% of Cultivar Capital Inc.’s investment portfolio, making the stock its 17th largest position.

Other institutional investors also recently modified their holdings of the company. Marquette Asset Management LLC increased its position in Danaher by 192.1% in the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 73 shares during the period. N.E.W. Advisory Services LLC bought a new position in Danaher during the second quarter worth about $25,000. Main Street Group LTD acquired a new stake in shares of Danaher in the 1st quarter valued at approximately $25,000. Field & Main Bank acquired a new position in Danaher during the second quarter valued at approximately $29,000. Finally, Evolution Wealth Management Inc. increased its stake in Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 104 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on DHR. Morgan Stanley boosted their target price on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. Stifel Nicolaus dropped their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Finally, Royal Bank Of Canada increased their target price on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Stock Performance

Shares of Danaher stock traded up $1.81 on Wednesday, hitting $224.65. The stock had a trading volume of 3,595,884 shares, compared to its average volume of 4,457,645. The stock has a market cap of $157.93 billion, a price-to-earnings ratio of 39.90, a price-to-earnings-growth ratio of 2.78 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The business’s 50 day moving average is $212.41 and its two-hundred day moving average is $195.13.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the previous year, the company posted $0.77 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. Analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.